Aktis Oncology Raises $84 Million To Advance Novel Targeted Alpha Radiopharmaceuticals
Amount Raised
$84 Million
Round Type
Funding Round
BostonBiotechnologyHealth CareTherapeuticsDescription
Aktis Oncology, a biotechnology company discovering and developing novel classes of targeted alpha radiopharmaceuticals to treat a broad range of solid tumors, today announced it has raised a Series A Extension financing of $84 million, bringing the total capital raised to date to $161 million. The extension included participation from new premier healthcare investors Cowen Healthcare Investments, MRL Ventures Fund, the therapeutics-focused corporate venture fund of Merck & Co., Inc., ArrowMark Partners, Mirae Asset Venture Investment, Timefolio Capital (formerly known as NS Investment), Pappas Capital, and other undisclosed participants. All existing investors MPM Capital, Vida Ventures, EcoR1 Capital, Octagon Capital, TCG Crossover, Bristol Myers Squibb, and Novartis participated in the financing.
Quick answer
Aktis Oncology raised $84 Million in a Funding Round round, dated August 25, 2022. Aktis Oncology is based in Boston, Massachusetts, United States.
- How much did Aktis Oncology raise?
- Aktis Oncology raised $84 Million in a Funding Round round on August 25, 2022.
- What does Aktis Oncology do?
- Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers.
- Where is Aktis Oncology based and how big is it?
- Aktis Oncology is based in Boston, Massachusetts, United States. Fundz records about 41 employees.
- Who are the decision-makers at Aktis Oncology?
- Fundz holds 1 contact at Aktis Oncology. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biotechnology around the same time
Companies in the same sectors as Aktis Oncology that raised within 45 days of this round, from Fundz verified event records.
- RadioMedix raised $40M (Series A) on October 7, 2022.
- NewcelX raised $4M (Seed) on October 7, 2022.
- Valitor raised an undisclosed amount (Series B) on October 5, 2022.
- Vergent Bioscience raised $22M (Series B) on October 4, 2022.
- Cellarity raised $121M (Series C) on October 4, 2022.
- Gamida Cell raised $25M (Funding Round) on September 28, 2022.
Who to call at Aktis Oncology, and when
A new round usually means Aktis Oncology is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day Aktis Oncology raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Aktis Oncology, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Aktis Oncology. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Aktis Oncology raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
Aktis Oncology raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.